ライフサイエンスコーパス: dexmedetomidine

1 ing alpha2 adrenergic receptor (AR) agonist (dexmedetomidine).

2 3.0 +/- 0.2 to 19.1 +/- 0.8 Hz (20 microg/kg dexmedetomidine).

3 edications such as midazolam, clonidine, and dexmedetomidine.

4 More adverse effects were associated with dexmedetomidine.

5 nes (midazolam and lorazepam), propofol, and dexmedetomidine.

6 ewer agents such as etomidate, propofol, and dexmedetomidine.

7 w update in the diverse uses of the sedative dexmedetomidine.

8 es, mechanism of action, and side effects of dexmedetomidine.

9 anagement include clonidine, tizanidine, and dexmedetomidine.

10 ay, intraoperative steroid bolus, and use of dexmedetomidine.

11 pamezole, reversed the functional effects of dexmedetomidine.

12 ness and recovery using the alpha(2)-agonist dexmedetomidine.

13 is needed to evaluate the clinical impact of dexmedetomidine.

14 ssign patients to receive either intravenous dexmedetomidine (0.1 mug/kg per h, from intensive care u

15 Dexmedetomidine (0.2-1.4 microg/kg per hour [n = 244]) o

16 otocol with lorazepam and were randomized to dexmedetomidine 1.2 mug/kg/hr (high dose), 0.4 mug/kg/hr

17 e biological activity of the present series, dexmedetomidine (1), and conformationally restrained ana

18 e, and after subsequent injection of saline, dexmedetomidine (100 mug/kg IV), or clonidine (200 mug/k

19 Dexmedetomidine (100 mug/kg, i.p.) prevented and reverse

20 mechanical ventilation appeared shorter with dexmedetomidine (123 hours [IQR, 67-337]) vs midazolam (

21 ylephrine (-25 +/- 4 versus -45 +/- 5%), and dexmedetomidine (-22 +/- 4 versus -44 +/- 3%) were all s

22 14%] of 350 patients) than in patients given dexmedetomidine (23 [7%] of 350 patients; 0.44, 0.26-0.7

23 mic administration of the alpha2-AR agonists dexmedetomidine (25 mug/kg, i.v.) and clonidine (100 mug

24 placebo (62 [18%] of 350 patients) than with dexmedetomidine (34 [10%] of 350 patients; 0.50, 0.32-0.

25 5) vs. benzodiazepines (31.1%, 30.7-31.5) or dexmedetomidine (4.0%, 3.8-4.2).

26 4 hours [IQR, 92-380]; P = .03) but not with dexmedetomidine (97 hours [IQR, 45-257]) vs propofol (11

27 The effects of dexmedetomidine, a highly selective alpha(2)-adrenocepto

28 e investigated whether prophylactic low-dose dexmedetomidine, a highly selective alpha2 adrenoceptor

29 We found that dexmedetomidine, a specific agonist of alpha-2 AR was ve

30 Dexmedetomidine abolished these increases, whereas intra

31 During the group comparison phase, dexmedetomidine achieved a higher percentage of time in

32 Similarly, dexmedetomidine administered after lipopolysaccharide ca

33 ry hypothesis tested was that intraoperative dexmedetomidine administration would reduce postoperativ

34 lly the same for natural sleep and following dexmedetomidine administration, but a sudden change in p

35 Dexmedetomidine allowed for the preservation of satisfac

36 ions of phenylephrine (alpha(1)-agonist) and dexmedetomidine (alpha(2)-agonist) during moderate rhyth

37 ions of phenylephrine (alpha(1)-agonist) and dexmedetomidine (alpha(2)-agonist) during rhythmic handg

38 release), phenylephrine (alpha1-agonist) and dexmedetomidine (alpha2-agonist) were assessed.

39 nnulated rats and their hypnotic response to dexmedetomidine (an alpha2 agonist) was determined.

40 Dexmedetomidine, an alpha(2)-agonist available for ICU s

41 Dexmedetomidine, an alpha-2-adrenergic agonist, causes a

42 Dexmedetomidine, an alpha2 adrenergic agonist, is a usef

43 Dexmedetomidine, an alpha2-adrenergic agonist, produces

44 A total of 342 patients (105 dexmedetomidine and 237 propofol) were included in the a

45 e significantly greater than those following dexmedetomidine and atipamezole.

46 Dexmedetomidine and etomidate are the subjects of invest

47 This investigation compared the actions of dexmedetomidine and halothane on the processed EEG and o

48 There was no difference between dexmedetomidine and midazolam in time at targeted sedati

49 nts were not statistically different between dexmedetomidine and placebo (159 mg vs 181 mg).

50 erence in postoperative delirium between the dexmedetomidine and placebo groups (12.2% [23 of 189] vs

51 rs of initiating study drug were similar for dexmedetomidine and placebo groups, respectively.

52 Dexmedetomidine and propofol are commonly used sedatives

53 cts in neurocritical care patients receiving dexmedetomidine and propofol.

54 Modern anesthetic medications such as dexmedetomidine and proven techniques such as awake fibe

55 9.6 +/- 0.7 to 5.9 +/- 0.8 Hz (20 microg/kg dexmedetomidine), and 95% power frequency from 23.0 +/-

56 outcomes, none were significantly worse with dexmedetomidine, and several showed statistically signif

57 iprostate cancer drug bicalutamide, sedative dexmedetomidine, and two antifungals ravuconazole and po

58 After excluding controls exposed to dexmedetomidine at a later time in the hospitalization,

59 d to early goal-directed sedation received a dexmedetomidine-based algorithm targeted to light sedati

60 urgery population has also been studied with dexmedetomidine because of its adequate sedation and les

61 Monitoring for bradycardia is needed with dexmedetomidine but the occurrence may be lessened with

62 Dexmedetomidine can decrease emergence agitation and has

63 etamine during anesthetic induction and with dexmedetomidine compared with other sedation strategies

64 The nonsubtype-selective alpha2 agonist dexmedetomidine completely blocked the contractile respo

65 l hypothesis that central sympatholysis with dexmedetomidine constitutes a highly effective counterme

66 The results indicate that dexmedetomidine decreases both GABAergic and glycinergic

67 At the clinically relevant doses, dexmedetomidine decreases cerebral blood flow and cerebr

68 ared with 1125 controls, the group receiving dexmedetomidine demonstrated significantly fewer tachyar

69 The administration of dexmedetomidine (DEX) at a low dose (2 microg/kg bolus i

70 Dexmedetomidine (DEX) may provide a sedation level that

71 The alpha-2 adrenergic agonist dexmedetomidine (Dex), 3-300 microg/kg, i.p., decreased

72 Dexmedetomidine (Dex), a potent, selective alpha-2 adren

73 Dexmedetomidine (DEX; Precedex) is an alpha-2 adrenergic

74 rtheless, these reports indicate that use of dexmedetomidine does not interfere with electrophysiolog

75 Intraoperative dexmedetomidine does not prevent postoperative delirium.

76 rine and the highly selective alpha2 agonist dexmedetomidine each reversed the VLPO depolarization in

77 The concurrent release of dexmedetomidine enhanced the efficacy of released local

78 ction (measured using VAS) was improved with dexmedetomidine (estimated score difference vs midazolam

79 uch more common than with benzodiazepines or dexmedetomidine, even for patients mechanically ventilat

80 Although dexmedetomidine exposure in the immediate postoperative

81 However, intraoperative use of dexmedetomidine for prevention of delirium has not been

82 Anesthesiologists are evaluating the use of dexmedetomidine for sedation of children and new reports

83 Adjunctive dexmedetomidine for severe alcohol withdrawal maintains

84 tive delirium was significantly lower in the dexmedetomidine group (32 [9%] of 350 patients) than in

85 More patients in the dexmedetomidine group (42% vs 31%; P = .61) were able to

86 ized incorrectly, leaving 39 patients in the dexmedetomidine group and 32 patients in the placebo gro

87 versus before study drug was greater in the dexmedetomidine group compared with the placebo group (-

88 rate adjustments occurred more often in the dexmedetomidine group compared with the placebo group (5

89 nd low-dose groups were combined as a single dexmedetomidine group for primary analysis with secondar

90 Bradycardia occurred more frequently in the dexmedetomidine group versus placebo group (25% vs 0%, p

91 e 12-month time to death was 363 days in the dexmedetomidine group vs 188 days in the lorazepam group

92 time within the target RASS range (77.3% for dexmedetomidine group vs 75.1% for midazolam group; diff

93 The 28-day mortality in the dexmedetomidine group was 17% vs 27% in the lorazepam gr

94 rol group) were compared with nonresponders (dexmedetomidine group).

95 be randomized to either the propofol or the dexmedetomidine group.

96 Dexmedetomidine has been demonstrated to provide a succe

97 Dexmedetomidine has been used effectively for sedation d

98 Clonidine and dexmedetomidine have many similar or superior qualities

99 Propofol and dexmedetomidine have not been rigorously tested in compa

100 on of, the loss of righting reflex following dexmedetomidine; hypnotic response had normalized 8 d af

101 ies; the PRODEX trial compared propofol with dexmedetomidine in 31 centers in 6 European countries an

102 The MIDEX trial compared midazolam with dexmedetomidine in ICUs of 44 centers in 9 European coun

103 The findings support the use of dexmedetomidine in patients such as these.

104 application of an alpha-2-adrenergic agonist dexmedetomidine in the anesthetic management of function

105 is responsible for the hypnotic response to dexmedetomidine in the locus coeruleus of the rat.

106 managed with an antipsychotic and, possibly, dexmedetomidine in treatment-refractory cases.

107 mouse lightly anesthetized with isoflurane, dexmedetomidine increased behavioral arousal and reduced

108 Dexmedetomidine increased ventilator-free hours at 7 day

109 st, phenylephrine, or full alpha(2)-agonist, dexmedetomidine, indicated that the behavioral effects o

110 These results provide a mechanism for dexmedetomidine induced bradycardia and has implications

111 Thus, we hypothesized that dexmedetomidine-induced altered arousal would manifest w

112 of age (n = 15, 6 males) at baseline, during dexmedetomidine-induced altered arousal, and recovery st

113 Dexmedetomidine induces sedation via different central n

114 Dexmedetomidine infusion (0.5 microg/kg/h) during surger

115 etic tone during cardiac surgery, a low-dose dexmedetomidine infusion has been utilized.

116 h individualized targeted sedation, use of a dexmedetomidine infusion resulted in more days alive wit

117 Dexmedetomidine is a relatively new representative for p

118 Dexmedetomidine is a selective alpha2 adrenoreceptor ago

119 Dexmedetomidine is a useful medication with many clinica

120 Dexmedetomidine is an anesthetic that alters the level o

121 ot associated with delirium, and that use of dexmedetomidine is associated with a lower delirium prev

122 Dexmedetomidine is commonly used after congenital heart

123 The combination of buspirone and dexmedetomidine is comparably effective while avoiding t

124 Dexmedetomidine is emerging as an effective therapeutic

125 antipsychotics, barbiturates, propofol, and dexmedetomidine) is detailed.

126 The roles of clonidine, dexmedetomidine, ketamine and nalbuphine in the treatmen

127 Propofol, dexmedetomidine, ketamine and remifentanil may be used i

128 tral medial thalamus, occurs at the point of dexmedetomidine loss of righting reflex.

129 troduced into the critical care unit such as dexmedetomidine may also provide a greater ability to ac

130 evidence indicates that the alpha(2) agonist dexmedetomidine may have distinct advantages.

131 Sedation with dexmedetomidine, midazolam, or propofol; daily sedation

132 Dexmedetomidine/midazolam ratio in time at target sedati

133 us dexmedetomidine (n = 3), lorazepam versus dexmedetomidine (n = 1), midazolam versus propofol (n =

134 s enrolling 1,235 patients: midazolam versus dexmedetomidine (n = 3), lorazepam versus dexmedetomidin

135 ssigned to receive either placebo (n=350) or dexmedetomidine (n=350).

136 medetomidine, n = 227; propofol, n = 214, vs dexmedetomidine, n = 223).

137 -protocol population (midazolam, n = 233, vs dexmedetomidine, n = 227; propofol, n = 214, vs dexmedet

138 r more than 24 hours (midazolam, n = 251, vs dexmedetomidine, n = 249; propofol, n = 247, vs dexmedet

139 medetomidine, n = 249; propofol, n = 247, vs dexmedetomidine, n = 251).

140 ll voltage clamp methodology, the actions of dexmedetomidine on excitatory glutamatergic and inhibito

141 ndomly administered halothane or intravenous dexmedetomidine (on separate days).

142 Patients were sedated with dexmedetomidine or lorazepam for as many as 120 hours.

143 Use of dexmedetomidine or propofol rather than a benzodiazepine

144 Continuous sedation with dexmedetomidine or propofol.

145 e in neurocritical care patients who receive dexmedetomidine or propofol.

146 led trial that randomly assigned patients to dexmedetomidine or saline placebo infused during surgery

147 aine (2 mg/kg) alone and in combination with dexmedetomidine or saline.

148 Bedside nursing staff administered dexmedetomidine (or placebo) initially at a rate of 0.5

149 urrent controlled data suggest that use of a dexmedetomidine- or propofol-based sedation regimen rath

150 Halothane and dexmedetomidine produced differing effects on level of c

151 d a lack of response to tail clamping, while dexmedetomidine produced profound sedation, with preserv

152 hasone, rivastigmine, risperidone, ketamine, dexmedetomidine, propofol, and clonidine) reduced the ri

153 et sedation was 1.07 (95% CI, 0.97-1.18) and dexmedetomidine/propofol, 1.00 (95% CI, 0.92-1.08).

154 Dexmedetomidine reduced duration of mechanical ventilati

155 aluate whether an intraoperative infusion of dexmedetomidine reduces postoperative delirium.

156 Sedation with dexmedetomidine resulted in more days alive without deli

157 Continuous sedation with dexmedetomidine results in significantly lower total int

158 warranted to delineate an optimal regimen of dexmedetomidine sedation and any dose-related influence

159 to determine the safety and effectiveness of dexmedetomidine sedation compared to the standard used p

160 ibing respiratory and hemodynamic aspects of dexmedetomidine sedation have also been published.

161 Emerging literature suggests that dexmedetomidine sedation in critical care units is assoc

162 In the study conditions, dexmedetomidine shows to be useful as a rescue drug for

163 r non-cardiac surgery, prophylactic low-dose dexmedetomidine significantly decreases the occurrence o

164 Patients sedated with dexmedetomidine spent more time within 1 RASS point of t

165 to light by co-delivering a second compound, dexmedetomidine, that potentiates the effect of delivere

166 With dexmedetomidine, the changes occurred simultaneously in

167 edge, this report describes the first use of dexmedetomidine to facilitate opioid withdrawal in child

168 Administration of dexmedetomidine to facilitate the discontinuation of opi

169 l sedation and local anesthesia, addition of dexmedetomidine to intravenous anesthesia, and defining

170 The Dexmedetomidine to Lessen ICU Agitation (DahLIA) study w

171 in the intensive care unit, the addition of dexmedetomidine to standard care compared with standard

172 The administration of the alpha 2-agonist, dexmedetomidine, to HTM cells resulted in a 90% inhibiti

173 n time to extubation was 1.9 days shorter in dexmedetomidine-treated patients (3.7 days [95% CI, 3.1

174 At comparable sedation levels, dexmedetomidine-treated patients spent less time on the

175 um during treatment was 54% (n = 132/244) in dexmedetomidine-treated patients vs 76.6% (n = 93/122) i

176 Dexmedetomidine-treated patients were more likely to dev

177 , the study examined the correlation between dexmedetomidine use and postoperative cognitive change.

178 Clinical experience of dexmedetomidine use in functional neurosurgery is limite

179 gery, we examined for an association between dexmedetomidine use in the immediate postoperative perio

180 Dexmedetomidine vs midazolam patients had more hypotensi

181 function trial, which compared sedation with dexmedetomidine vs. lorazepam in mechanically ventilated

182 Direct cost of dexmedetomidine was 17 times greater than haloperidol, b

183 Dexmedetomidine was administered in the immediate postop

184 cluding drug acquisition cost, sedation with dexmedetomidine was associated with a median total inten

185 dine at a later time in the hospitalization, dexmedetomidine was associated with increased odds of br

186 The most notable adverse effect of dexmedetomidine was bradycardia.

187 Dexmedetomidine was effective in blocking these sympatho

188 4 (3.5%) standard sedation patient-days when dexmedetomidine was given.

189 For each trial, we tested whether dexmedetomidine was noninferior to control with respect

190 receiving prolonged mechanical ventilation, dexmedetomidine was not inferior to midazolam and propof

191 nced baseline characteristics, allocation to dexmedetomidine was significantly associated with earlie

192 Dexmedetomidine was subsequently discontinued and the pa

193 Propofol and dexmedetomidine were the most commonly restricted medica

194 ese procedures can be provided by the use of dexmedetomidine, with or without the addition of remifen